These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8393333)

  • 41. Transport and in vivo elimination of cysteinyl leukotrienes.
    Keppler D; Müller M; Klünemann C; Guhlmann A; Krauss K; Müller J; Berger U; Leier I; Mayatepek E
    Adv Enzyme Regul; 1992; 32():107-16. PubMed ID: 1496913
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Measurement of urinary leukotrienes by reversed-phase liquid chromatography and radioimmunoassay.
    Tagari P; Ethier D; Carry M; Korley V; Charleson S; Girard Y; Zamboni R
    Clin Chem; 1989 Mar; 35(3):388-91. PubMed ID: 2537686
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The in vivo production of peptide leukotrienes after pulmonary anaphylaxis in the rat.
    Foster A; Letts G; Charleson S; Fitzsimmons B; Blacklock B; Rokach J
    J Immunol; 1988 Nov; 141(10):3544-50. PubMed ID: 2846689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Urinary LTE4 excretion in antigen-provoked asthmatic patients treated with the inhaled LTD4 antagonist, L-648,051.
    Rasmussen JB; Eriksson LO; Tagari P; Margolskee DJ; Girard Y; Andersson KE
    Allergy; 1992 Dec; 47(6):599-603. PubMed ID: 1337423
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhanced excretion of urinary leukotriene E4 in coronary artery disease and after coronary artery bypass surgery.
    Allen SP; Sampson AP; Piper PJ; Chester AH; Ohri SK; Yacoub MH
    Coron Artery Dis; 1993 Oct; 4(10):899-904. PubMed ID: 8269196
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum complement mediates endotoxin-induced cysteinyl leukotriene formation in rats in vivo.
    Jaeschke H; Raftery MJ; Justesen U; Gaskell SJ
    Am J Physiol; 1992 Dec; 263(6 Pt 1):G947-52. PubMed ID: 1476201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Leukotriene E4 elimination and metabolism in normal human subjects.
    Sala A; Voelkel N; Maclouf J; Murphy RC
    J Biol Chem; 1990 Dec; 265(35):21771-8. PubMed ID: 2174886
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolism and analysis of cysteinyl leukotrienes in the monkey.
    Denzlinger C; Guhlmann A; Scheuber PH; Wilker D; Hammer DK; Keppler D
    J Biol Chem; 1986 Nov; 261(33):15601-6. PubMed ID: 3023324
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological profile of leukotrienes E4, N-acetyl E4 and of four of their novel omega- and beta-oxidative metabolites in airways of guinea-pig and man in vitro.
    Samhoun MN; Conroy DM; Piper PJ
    Br J Pharmacol; 1989 Dec; 98(4):1406-12. PubMed ID: 2558763
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cysteinyl leukotrienes in the urine of patients with liver diseases.
    Uemura M; Buchholz U; Kojima H; Keppler A; Hafkemeyer P; Fukui H; Tsujii T; Keppler D
    Hepatology; 1994 Oct; 20(4 Pt 1):804-12. PubMed ID: 7927219
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Leukotriene uptake by hepatocytes and hepatoma cells.
    Leier I; Müller M; Jedlitschky G; Keppler D
    Eur J Biochem; 1992 Oct; 209(1):281-9. PubMed ID: 1327771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Uptake, production and metabolism of cysteinyl leukotrienes in the isolated perfused rat liver. Inhibition of leukotriene uptake by cyclosporine.
    Hagmann W; Parthé S; Kaiser I
    Biochem J; 1989 Jul; 261(2):611-6. PubMed ID: 2549977
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased generation of cysteinyl leukotrienes in Kawasaki disease.
    Mayatepek E; Lehmann WD
    Arch Dis Child; 1995 Jun; 72(6):526-7. PubMed ID: 7618941
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolism and excretion of exogenous [3H]-LTC4 in primates.
    Tagari P; Foster A; Delorme D; Girard Y; Rokach J
    Prostaglandins; 1989 Jun; 37(6):629-40. PubMed ID: 2549573
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased excretion of endogenous urinary leukotriene E4 in extrahepatic cholestasis.
    Mayatepek E; Pecher G
    Clin Chim Acta; 1993 Sep; 218(2):185-92. PubMed ID: 8306442
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased production of cysteinyl leukotrienes in hepatorenal syndrome.
    Moore KP; Taylor GW; Maltby NH; Siegers D; Fuller RW; Dollery CT; Williams R
    J Hepatol; 1990 Sep; 11(2):263-71. PubMed ID: 2174935
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Syntheses of leukotriene-derivatives.
    Bestmann HJ; Röder T
    Eicosanoids; 1992; 5 Suppl():S1-3. PubMed ID: 1333249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteristics of sinusoidal uptake and biliary excretion of cysteinyl leukotrienes in perfused rat liver.
    Wettstein M; Gerok W; Häussinger D
    Eur J Biochem; 1990 Jul; 191(1):251-5. PubMed ID: 2165907
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impaired degradation of leukotrienes in patients with peroxisome deficiency disorders.
    Mayatepek E; Lehmann WD; Fauler J; Tsikas D; Frölich JC; Schutgens RB; Wanders RJ; Keppler D
    J Clin Invest; 1993 Mar; 91(3):881-8. PubMed ID: 8450067
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elevated urinary leukotriene E4 excretion in patients with ARDS and severe burns.
    Westcott JY; Thomas RB; Voelkel NF
    Prostaglandins Leukot Essent Fatty Acids; 1991 Jul; 43(3):151-8. PubMed ID: 1651513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.